NASDAQ:EXAI Exscientia (EXAI) Stock Price, News & Analysis → The Overlooked Retirement Asset You Probably Don’t Own (From Crypto 101 Media) (Ad) Free EXAI Stock Alerts $5.20 +0.07 (+1.36%) (As of 05/17/2024 ET) Add Compare Share Share Today's Range$5.02▼$5.2350-Day Range$3.99▼$6.8652-Week Range$3.86▼$9.12Volume949,901 shsAverage Volume452,807 shsMarket Capitalization$628.63 millionP/E RatioN/ADividend YieldN/APrice Target$9.75 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get Exscientia alerts: Email Address Exscientia MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.50 Rating ScoreUpside/Downside87.5% Upside$9.75 Price TargetShort InterestBearish3.71% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.00Based on 16 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($1.76) to ($1.70) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.36 out of 5 starsMedical Sector739th out of 914 stocksBiological Products, Except Diagnostic Industry126th out of 153 stocks 3.3 Analyst's Opinion Consensus RatingExscientia has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 2 buy ratings, 2 hold ratings, and no sell ratings.Amount of Analyst CoverageExscientia has only been the subject of 1 research reports in the past 90 days.Read more about Exscientia's stock forecast and price target. Previous Next 2.0 Short Interest Percentage of Shares Shorted3.71% of the float of Exscientia has been sold short.Short Interest Ratio / Days to CoverExscientia has a short interest ratio ("days to cover") of 5.9.Change versus previous monthShort interest in Exscientia has recently increased by 0.23%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldExscientia does not currently pay a dividend.Dividend GrowthExscientia does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for EXAI. Previous Next 1.1 News and Social Media Coverage News SentimentExscientia has a news sentiment score of 0.00. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.42 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 16 news articles for Exscientia this week, compared to 3 articles on an average week.Search InterestOnly 12 people have searched for EXAI on MarketBeat in the last 30 days. This is a decrease of -29% compared to the previous 30 days.MarketBeat FollowsOnly 27 people have added Exscientia to their MarketBeat watchlist in the last 30 days. This is a decrease of -7% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Exscientia insiders have not sold or bought any company stock.Percentage Held by Insiders16.40% of the stock of Exscientia is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions41.58% of the stock of Exscientia is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Exscientia's insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Exscientia are expected to grow in the coming year, from ($1.76) to ($1.70) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Exscientia is -3.51, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Exscientia is -3.51, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioExscientia has a P/B Ratio of 1.42. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Exscientia's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Crypto 101 MediaThe Overlooked Retirement Asset You Probably Don’t Own4 out of 5 Americans believe we’re on the brink of a retirement crisis. Luckily, in these unprecedented times, we have an unprecedented solution. Once considered a “fringe” investment, the crypto market is now taking the world by storm.Click here to access the Crypto Retirement Blueprint now. About Exscientia Stock (NASDAQ:EXAI)Exscientia plc, an artificial intelligence (AI) driven Pharma-tech company, engages in design and develop differentiated medicines for diseases with high unmet patient needs. The company's lead product candidate GTAEXS617, a CDK7 inhibitor, which is currently in a Phase 1/2 trial to manage the potential toxicities associated with CDK7 as well as optimizing pharmacokinetics for maximizing on-target efficacy. It is also involved in the development of EXS4318, a PKC-theta inhibitor, under Phase 1 clinical trial for inflammation and immunology indications; EXS74539, a LSD1 inhibitor, under preclinical studies for SCLC, AML, and potential additional indications; EXS73565, a MALT1 inhibitor, under preclinical studies for multiple hematology indications; and DSP-0038, currently in Phase 1 studies. The company has collaboration agreements with Merck KGaA, Bristol Myers Squibb, Sanofi, Bill & Melinda Gates Foundation, Charité Universitätsmedizin Berlin, Rallybio, and GT Apeiron Therapeutics. Exscientia plc was founded in 2012 and is headquartered in Oxford, the United Kingdom.Read More EXAI Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart EXAI Stock News HeadlinesMay 19 at 2:47 PM | stockhouse.comROSEN, A LEADING AND RANKED FIRM, Encourages Exscientia p.l.c Investors to Secure Counsel Before Important Deadline in Securities Class Action - EXAIMay 19 at 1:52 AM | americanbankingnews.comExscientia (EXAI) Scheduled to Post Quarterly Earnings on TuesdayMay 19 at 12:12 AM | theglobeandmail.comROSEN, NATIONAL INVESTOR COUNSEL, Encourages Exscientia p.l.c Investors to Secure Counsel Before Important Deadline in Securities Class Action - EXAIMay 18 at 7:12 PM | stockhouse.comSHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of ExscientiaMay 17 at 11:00 AM | prnewswire.comEXAI Investors Have Opportunity to Lead Exscientia p.l.c. Securities Fraud LawsuitMay 16 at 12:00 PM | prnewswire.comSHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Exscientia p.l.c. of Class Action Lawsuit and Upcoming Deadlines - EXAIMay 16 at 1:34 AM | americanbankingnews.comExscientia (NASDAQ:EXAI) versus Anavex Life Sciences (NASDAQ:AVXL) Financial ReviewMay 15, 2024 | prnewswire.comROSEN, SKILLED INVESTOR COUNSEL, Encourages Exscientia p.l.c Investors to Secure Counsel Before Important Deadline in Securities Class Action - EXAIMay 15, 2024 | finance.yahoo.comExscientia plc (EXAI) Stock Price, News, Quote & History - Yahoo FinanceMay 15, 2024 | prnewswire.comClass Action Filed Against Exscientia plc (EXAI) Seeking Recovery for Investors - Contact Levi & KorsinskyMay 14, 2024 | prnewswire.comEXAI Investors Have Opportunity to Lead Exscientia p.l.c. Securities Fraud LawsuitMay 14, 2024 | businesswire.comExscientia to Report First Quarter 2024 Financial Results on May 21, 2024May 14, 2024 | prnewswire.comShareholders that lost money on Exscientia plc(EXAI) should contact The Gross Law Firm about pending Class Action - EXAIMay 13, 2024 | businesswire.comKirby McInerney LLP Reminds Exscientia p.l.c. (EXAI) Investors of Class Action Filing and Encourages Investors to Contact the FirmMay 13, 2024 | prnewswire.comLevi & Korsinsky Notifies Exscientia plc Investors of a Class Action Lawsuit and Upcoming Deadline - EXAIMay 12, 2024 | markets.businessinsider.comINVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of ExscientiaMay 10, 2024 | businesswire.comEXAI Stockholders with Large Losses Should Contact Robbins LLP for Information About the Class Action Against Exscientia plcMay 10, 2024 | businesswire.comGlancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Exscientia p.l.c. (EXAI)May 9, 2024 | stockhouse.comROSEN, TOP RANKED GLOBAL COUNSEL, Encourages Exscientia p.l.c Investors to Secure Counsel Before Important Deadline in Securities Class Action - EXAIMay 8, 2024 | prnewswire.comROSEN, A HIGHLY RECOGNIZED LAW FIRM, Encourages Exscientia p.l.c Investors to Secure Counsel Before Important Deadline in Securities Class Action - EXAIMay 8, 2024 | prnewswire.comExscientia plc Securities Fraud Class Action Lawsuit Pending: Contact Levi & Korsinsky Before June 25, 2024 to Discuss Your Rights - EXAIMay 8, 2024 | prnewswire.comEXAI INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Exscientia p.l.c. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!May 7, 2024 | markets.businessinsider.comSHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of ExscientiaMay 7, 2024 | businesswire.comGlancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces the Filing of a Securities Class Action on Behalf of Exscientia p.l.c. (EXAI) InvestorsMay 7, 2024 | prnewswire.comExscientia plc Sued for Securities Law Violations - Investors Should Contact The Gross Law Firm Before June 25, 2024 to Discuss Your Rights - EXAISee More Headlines Receive EXAI Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Exscientia and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/21/2024Today5/19/2024Next Earnings (Confirmed)5/21/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryN/A Current SymbolNASDAQ:EXAI CUSIPN/A CIK1865408 Webwww.exscientia.ai Phone44-0-18-6581-8941FaxN/AEmployees483Year FoundedN/APrice Target and Rating Average Stock Price Target$9.75 High Stock Price Target$13.00 Low Stock Price Target$7.00 Potential Upside/Downside+87.5%Consensus RatingModerate Buy Rating Score (0-4)2.50 Research Coverage4 Analysts Profitability EPS (Most Recent Fiscal Year)($1.48) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-181,560,000.00 Net Margins-737.10% Pretax Margin-807.26% Return on Equity-36.44% Return on Assets-26.39% Debt Debt-to-Equity Ratio0.05 Current Ratio6.22 Quick Ratio6.22 Sales & Book Value Annual Sales$25.60 million Price / Sales24.56 Cash FlowN/A Price / Cash FlowN/A Book Value$3.66 per share Price / Book1.42Miscellaneous Outstanding Shares120,890,000Free Float101,062,000Market Cap$628.63 million OptionableOptionable Beta0.82 10 Best Cheap Stocks to Buy NowMarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.Get This Free Report Key ExecutivesDr. David Hallett Ph.D. (Age 55)Chief Scientific Officer, Interim CEO, Principal Executive Officer & Executive Director Mr. Ben R. Taylor (Age 47)CFO, Chief Strategy Officer & Executive Director Comp: $524.4kDr. Michael Krams M.D. (Age 63)Chief Medical Officer Ms. Eileen Jennings-BrownChief Information OfficerMs. Sara ShermanVice President of Investor RelationsMr. Dan IrelandVice President of Legal & Company SecretaryMr. Parker MossExecutive Vice President of Corporate DevelopmentMs. Caroline RowlandChief People OfficerMr. Richard LawChief Business OfficerDr. John P. Overington Ph.D.Chief Data OfficerMore ExecutivesKey CompetitorsiTeos TherapeuticsNASDAQ:ITOSAdaptive BiotechnologiesNASDAQ:ADPTValnevaNASDAQ:VALNHilleVaxNASDAQ:HLVXKyverna TherapeuticsNASDAQ:KYTXView All CompetitorsInstitutional OwnershipPlatinum Investment Management Ltd.Sold 141,500 shares on 5/14/2024Ownership: 3.265%EntryPoint Capital LLCBought 5,784 shares on 5/14/2024Ownership: 0.026%Mitsubishi UFJ Trust & Banking CorpSold 25,530 shares on 5/10/2024Ownership: 0.125%Susquehanna Portfolio Strategies LLCSold 13,169 shares on 5/7/2024Ownership: 0.028%Baillie Gifford & Co.Sold 116,075 shares on 5/1/2024Ownership: 3.784%View All Institutional Transactions EXAI Stock Analysis - Frequently Asked Questions Should I buy or sell Exscientia stock right now? 4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Exscientia in the last year. There are currently 2 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" EXAI shares. View EXAI analyst ratings or view top-rated stocks. What is Exscientia's stock price target for 2024? 4 brokers have issued 1-year price objectives for Exscientia's stock. Their EXAI share price targets range from $7.00 to $13.00. On average, they anticipate the company's stock price to reach $9.75 in the next twelve months. This suggests a possible upside of 87.5% from the stock's current price. View analysts price targets for EXAI or view top-rated stocks among Wall Street analysts. How have EXAI shares performed in 2024? Exscientia's stock was trading at $6.41 at the beginning of the year. Since then, EXAI stock has decreased by 18.9% and is now trading at $5.20. View the best growth stocks for 2024 here. When is Exscientia's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 21st 2024. View our EXAI earnings forecast. How can I listen to Exscientia's earnings call? Exscientia will be holding an earnings conference call on Tuesday, May 21st at 8:30 AM Eastern. Interested parties can register for or listen to the call using this link. How were Exscientia's earnings last quarter? Exscientia plc (NASDAQ:EXAI) announced its quarterly earnings results on Thursday, March, 21st. The company reported ($0.42) EPS for the quarter, topping analysts' consensus estimates of ($0.44) by $0.02. The company had revenue of $3.10 million for the quarter, compared to analyst estimates of $41.63 million. Exscientia had a negative net margin of 737.10% and a negative trailing twelve-month return on equity of 36.44%. What ETF holds Exscientia's stock? First Trust Nasdaq Artificial Intelligence and Robotics ETF holds 1,443,583 shares of EXAI stock, representing 1.32% of its portfolio. When did Exscientia IPO? Exscientia (EXAI) raised $291 million in an IPO on Friday, October 1st 2021. The company issued 13,850,000 shares at a price of $20.00-$22.00 per share. Who are Exscientia's major shareholders? Exscientia's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Baillie Gifford & Co. (3.78%), Platinum Investment Management Ltd. (3.26%), Mitsubishi UFJ Trust & Banking Corp (0.13%), Susquehanna Portfolio Strategies LLC (0.03%), EntryPoint Capital LLC (0.03%) and China Universal Asset Management Co. Ltd. (0.01%). How do I buy shares of Exscientia? Shares of EXAI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:EXAI) was last updated on 5/19/2024 by MarketBeat.com Staff From Our Partners[URGENT] DO NOT Touch These AI Stocks!Weiss RatingsCEO of Biggest AI Chipmaker Just Dropped a Bombshell…Banyan Hill PublishingShocking $16T Elon Musk Crypto LeakCrypto 101 MediaUrgent Nvidia WarningAltimetryForget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THISParadigm PressMost important medical advance in 100 yearsThe Oxford Club41 banks launch ‘crypto dollar’Stansberry ResearchHe Is Giving Away BitcoinCrypto Swap Profits Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Exscientia plc Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.